The Soluble Guanylyl Cyclase Activator Bay 58-2667 Selectively Limits Cardiomyocyte Hypertrophy
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Soluble Guanylyl Cyclase Activator Bay 58-2667 Selectively Limits Cardiomyocyte Hypertrophy
Authors
Keywords
Fibroblasts, Superoxides, DNA synthesis, Protein synthesis, cGMP signaling, Fibrosis, Hemodynamics, Muscle cells
Journal
PLoS One
Volume 7, Issue 11, Pages e44481
Publisher
Public Library of Science (PLoS)
Online
2012-11-08
DOI
10.1371/journal.pone.0044481
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- cGMP becomes a drug target
- (2012) Jens Schlossmann et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- Nitroxyl (HNO) Stimulates Soluble Guanylyl Cyclase to Suppress Cardiomyocyte Hypertrophy and Superoxide Generation
- (2012) Eliane Q. Lin et al. PLoS One
- Soluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary Disease
- (2011) Johannes-Peter Stasch et al. CIRCULATION
- Soluble Guanylate Cyclase Stimulation Prevents Fibrotic Tissue Remodeling and Improves Survival in Salt-Sensitive Dahl Rats
- (2011) Sandra Geschka et al. PLoS One
- Expression and functional roles of guanylate cyclase isoforms in BRIN-BD11 β-cells
- (2011) Mark A. Russell et al. Islets
- The anti-aggregating effect of BAY 41-2272, a stimulator of soluble guanylyl cyclase, requires the presence of nitric oxide
- (2010) Séverine Roger et al. BRITISH JOURNAL OF PHARMACOLOGY
- Mechanisms of relaxant activity of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41-2272 in rat tracheal smooth muscle
- (2010) Haroldo A. Toque et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- BAY 41-2272 inhibits the development of chronic hypoxic pulmonary hypertension in rats
- (2010) Lise Bech Thorsen et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Anti-aggregating effect of BAY 58-2667, an activator of soluble guanylyl cyclase
- (2010) Séverine Roger et al. VASCULAR PHARMACOLOGY
- Regulation of VASP phosphorylation in cardiac myocytes: differential regulation by cyclic nucleotides and modulation of protein expression in diabetic and hypertrophic heart
- (2009) Juliano L. Sartoretto et al. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
- Cinaciguat, a soluble guanylate cyclase activator, causes potent and sustained pulmonary vasodilation in the ovine fetus
- (2009) Marc Chester et al. AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
- Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation
- (2009) LS Hoffmann et al. BRITISH JOURNAL OF PHARMACOLOGY
- B-Type Natriuretic Peptide: Endogenous Regulator of Myocardial Structure, Biomarker and Therapeutic Target
- (2009) Rebecca Ritchie et al. CURRENT MOLECULAR MEDICINE
- BAY 58-2667, a nitric oxide-independent guanylyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts
- (2009) T. Krieg et al. EUROPEAN HEART JOURNAL
- Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart
- (2009) Hiroyuki Masuyama et al. HYPERTENSION RESEARCH
- Exploiting cGMP-based therapies for the prevention of left ventricular hypertrophy: NO• and beyond
- (2009) Rebecca H. Ritchie et al. PHARMACOLOGY & THERAPEUTICS
- Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics
- (2009) Emily J. Tsai et al. PHARMACOLOGY & THERAPEUTICS
- Probing the presence of the ligand-binding haem in cellular nitric oxide receptors
- (2008) B Roy et al. BRITISH JOURNAL OF PHARMACOLOGY
- NO-independent activation of soluble guanylate cyclase prevents disease progression in rats with 5/6 nephrectomy
- (2006) Philipp Kalk et al. BRITISH JOURNAL OF PHARMACOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More